FIRST AIRED: May 23, 2017

Nice work! Enjoy the show!

×

You’re busy. We get it.

Stay on top of the news with our Editor’s Picks newsletter.

US Edition
Intl. Edition
Unsubscribe at any time. One click, it’s gone.

Thanks for signing up!

×

Transcript

00:00:00
billion dollars , and on a deeper strategic level it's going to get a number of things as well it's going to get botox and cultivating a portfolio of other drugs they can add to existing on the platform of of patented drugs and and with backing ultimately do for a fighter exposition to split up potential and if they execute on it buyers will become to companies one with a concentrated portfolio generic drugs and the other will be a high growth high margin a patented drug companies , but that's not all either get an elegant but I could bring with it a smaller tax bill by switching partners headquarters to arrogance hometown of Dublin Ireland which had a lower corporate tax rate than the U. S. idea however has tried something like this before last year for the same reason it attempted to buy Anglo Swedish giant academica but that failed , Washington could be a problem the U. S. doesn't look warmly on this kind of tax dodging maneuver a crackdown on so called tax inversion mergers